Tuesday, 06. January 2009

Life sciences


Advanced genomics and its applications for health



Combating major diseases



Applications-orientated genomic approaches to medical knowledge and technologies



Combating cancer



Confronting the major communicable diseases linked to poverty



Specific support actions across thematic priority 1


Policy support

International co-operation

Reporting module


AGLAEA - DEVELOPMENT OF NOVEL ANIMAL MODELS OF GLUTAMATERGIC CENTRAL NERVOUS SYSTEM DISORDERS USING IN VIVO SIRNA AND TRANSGENIC APPROACHES (Life sciences, genomics and biotechnology for health) (2007-01-01 - 2009-12-31) (»add to infobox)



ACRONYM:AGLAEA
BUDGET:1.692.910 €
FUNDING:1.198.900 €
INSTRUMENT:Specific Targeted Research Project
PROGRAMME:Life sciences, genomics and biotechnology for health
Glutamate is the most abundant excitatory transmitter in the brain. However, very few models exist to explore the potential of drugs that modulate glutamate transmission. Because altered glutamate transmission is involved in numerous psychiatric diseases, there is a strong need for such models, to characterise the effects of hypo- and hyper-glutamatergic states on the onset and development of such diseases. AGLAEA will develop and characterise models of selective, partial knockdown of specific components of the brain glutamatergic system in mice. This will provide better comprehension of the implication of glutamate signalling in diseases such as schizophrenia, anxiety and cognitive disorders. AGLAEA will lead to breakthrough research on the neurobiological and neurochemical bases of psychiatric disorders and will enable the further testing of new drugs for treatment. In order to selectively turn off specific components of the glutamatergic pathways, an siRNA approach will be used. The effect of modulation of glutamate signalling will be characterised using functional MRI (fMRI) and microdialysis/microsensor analysis. Specific behavioural tests will be carried out on live animals for the assessment of glutamate-related psychiatric disorders. Furthermore, the data collected from siRNA experiments will be applied to the generation of transgenic mice, in which modulation of glutamate signaling will be induced at different stages of development. Therefore, AGLAEA will provide both the pharmaceutical and the academic world with potent models. These models will be used to test novel compounds and assess their therapeutic value and will benefit researchers investigating the neurobiological and neurochemical bases of those diseases. The consortium set up to reach the objectives of AGLAEA gathers 3 high tech SMEs, 2 academic groups and one large group for the management of the project (ALMA), representing all together 4 European countries (FR, HU, UK, NL).

COORDINATOR (1/1) 


Mark EPPING-JORDAN (Contact / ADDEX PHARMACEUTICALS FRANCE SAS (FR718 - Haute-Savoie) (FR - France))

PARTICIPANTS (5/5) 


Andras Janos DINNYES (Contact / BIOTALENTUM TUDASFEJLESZTO KFT (HU102 - Pest) (HU - Hungary))

Charles MARSDEN (Contact / THE UNIVERSITY OF NOTTINGHAM (UKF14 - Nottingham) (UK - Great Britain))

Bernard H. C. WESTERINK (Contact / RIJKSUNIVERSITEIT GRONINGEN (NL113 - Overig Groningen) (NL - Netherlands))

Thomas CREMERS (Contact / BRAINS ONLINE BV (NL113 - Overig Groningen) (NL - Netherlands))

Hana BILAK (Contact / ALMA CONSULTING GROUP SAS (FR231 - Eure) (FR - France))

RELATED THEMATIC AREAS (1/1) 

Studying the brain and combating diseases of the nervous system




SEARCH



»Advanced Search



SHORT CUTS

»Thematic areas

»Organisations

»Persons



INFOBOX (0/0) show all
Your infobox is empty


LifeCompetence is operated by AVEDAS.
LifeCompetence operated by AVEDAS
Contact: support@avedas.com


Powered by CONVERIS 2.0